Press Release

Press Release July 24, 2026 OneSource Announces Strong Q1FY27 Results Revenue up 37% YoY and EBITDA up 39% YoY Performance Highlights • Revenue of ₹4,490m, up 37% YoY and 5% QoQ, driven by growth in semaglutide commercial launch, new MSA contracts, and customer wins across businesses • EBITDA of ₹1,233m, up 39% YoY and 34% QoQ, with margins expanding to 27.5%, driven by operating leverage on higher semaglutide revenue • Adjusted PAT stood at ₹637m with adjusted EPS of ₹5.6 FY28 Guidance Reaffirmation • $400 million in organic revenue with 40% EBITDA margin Bangalore, India, July 24, 2026 – OneSource Specialty Pharma Limited (BSE:544292, NSE: ONESOURCE) today announced its consolidated financial results for the quarter ended June 30, 2026. Financial Highlights (In ₹ million) Particulars Q1FY27 Q4FY26 QoQ Q1FY26 YoY Revenues 4,490 4,282 5% 3,273 37% EBITDA 1,233 919 34% 885 39% EBITDA % 27.5% 21.5% 600bps 27.0% 43bps Adjusted PAT 637 390 63% 371 72% Adjusted EPS 5.6 3.4 63% 3.2 71% Note: Adjusted PAT and Adjusted EPS excludes exceptional items (Q1FY27: ₹43m, Q4FY26: gain ₹0.3m, Q1FY26: ₹29m) and scheme related intangible amortisation (₹344m in each quarter) Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the performance said, “We have started FY27 on a strong note, delivering robust growth in revenue and EBITDA, driven by commercialisation of semaglutide in Canada and India. We are excited to bring our second cartridge line into commercial operations in Q2, a significant milestone in our capacity expansion. Our biologics business gathered further momentum this quarter with the addition of yet another leading global biosimilar customer, reinforcing the strength of our integrated CDMO capabilities.” Detailed investor communication on the performance of the Company is attached. Press Release July 24, 2026 About OneSource Specialty Pharma Limited OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,600 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end- to-end solutions. For more information, please visit www.onesourcecdmo.com. For further information, please contact: Institutional Investors Corporate Communication Anurag Bhagania CFO Pallavi Panchmatia: +91 8951939181 Email: pallavi.panchmatia@onesourcecdmo.com Tejaswani Fotedar +91 9004331391 Abhilash Mukherjee: +91 89044 28907 Email: investor-relations@onesourcecdmo.com Email: abhilash.mukherjee@onesourcecdmo.com Harsh Sheth: +91 9870631557 Email: harsh.sheth@mslgroup.com Investor Presentation | Q1FY27 July 24th, 2026 Safe Harbor Statement Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", “seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements“. These forward-looking statements involve a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those suggested by the forward- looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Strong start to FY27 as semaglutide commercialisation scales and biologics gains momentum ( Q1FY27 Performance Snapshot ) “We have started FY27 on a strong note, delivering robust growth in ₹4,490m Revenue revenue and EBITDA, driven by commercialisation of semaglutide in $47.5m 5% QoQ 37% YoY Canada and India. We are excited to bring our second cartridge line into commercial operations in Q2, a significant milestone in our ₹1,233m EBITDA capacity expansion. Our biologics business gathered further $13.1m 34% QoQ 39% YoY momentum this quarter with the addition of yet another leading global biosimilar customer, reinforcing the strength of our integrated EBITDA margin 27.5% CDMO capabilities.” 600 bps QoQ 43 bps YoY ₹637m Adjusted PAT1 $6.7m 63% QoQ 72% YoY Neeraj Sharma CEO & MD Notes: All figures presented in $m have been converted using average exchange rate of USD = ₹94.507 1. Adjusted PAT excludes exceptional items (Q1FY27: ₹43m) and scheme related intangible amortisation (Q1FY27: ₹344m) Q1FY27: Semaglutide ramp-up delivering 39% YoY EBITDA growth In $m Q1FY27 QoQ Q1FY26 YoY Financial Snapshot Revenue 47.5 +5% 34.6 +37% EBITDA 13.1 +34% 9.4 +39% • Revenue of $47.5m/₹4,490m EBITDA margin (%) 27.5% +600bps 27.0% +43bps ↑5% QoQ and ↑37% YoY driven by growth in semaglutide Reported PAT 2.6 5x+ (0.0) Loss to Profit commercial launch, new MSA Adjusted PAT1 6.7 +63% 3.9 +72% contracts, and customer wins across Adjusted EPS1 ($) 0.06 +63% 0.03 +71% businesses In ₹m Q1FY27 QoQ Q1FY26 YoY • EBITDA of $13.1m/₹1,233m Revenue 4,490 +5% 3,273 +37% ↑ 34% QoQ and ↑ 39% YoY EBITDA 1,233 +34% 885 +39% with margins expanding to 27.5%, EBITDA margin (%) 27.5% +600bps 27.0% +43bps driven by operating leverage on higher semaglutide revenue Reported PAT 250 5x+ (2) Loss to Profit Adjusted PAT1 637 +63% 371 +72% Adjusted EPS1 (₹) 5.6 +63% 3.2 +71% Notes: All figures presented in $ have been converted using average exchange rate of USD = ₹94.507 and accordingly the prior period figures have been restated 1. Adjusted PAT and Adjusted EPS excludes exceptional items (Q1FY27: ₹43m, Q1FY26: ₹29m) and scheme related intangible amortisation (₹344m in each quarter) Business & Operational Updates Q1FY27 Expanded customer base, advanced capacity expansion, and deepened our biologics footprint Licensing/MSA deals 1. B braun Q1FY27 AT A GLANCE 2. Delbert 3. Aforell 4. Ibuprofen-Regular 5. Ibuprofen-Mini Expanding DDC capacity 2x 6. Ibuprofen+Diphenhydramine Commercial momentum 7. Tafamidis 8. Calcitriol 2nd cartridge line commercialising in Q2 ‘Sterile production 9. Alfacalcidol Expanding customer engagement across modalities, supported Progressing in line with our capacity expansion plan 10. Lupin days’1 11. Formycon by a robust and growing opportunity pipeline Building biologics business 4x New launches 1. PAR health 11 6 9 Signed a strategic biosimilars partnership $28m as on Feb 25 RFP funnel 2. MSN Funnel at all time high $101m as on 24 July 26 growth vs FY25 3. Natco $54m on 24 July 25 New wins 4. DRL 5. Orbicular 6. Eris New logos added, New launches 7. Corona bringing total across customers Continuing quality excellence 8. Mankind Active RFPs customers to 80+ and modalities 9. Glenmark in pipeline Stellar compliance track record maintained Regulatory inspections EU GMP, TGA GMP received across 2 sites and customer audits New logo 1. Lupin 2. Delbert DDC = Drug Device Combination 3. A forell 1. Total number of production days available across all lines 4. B Braun 5. Softgel Health 6. Formycon Strong and diverse customer base in semaglutide and 2 First-to-File in tirzepatide reinforce our leadership in GLP-1 20+ First and only CDMO with 3 G7 semaglutide approvals Suppl [Showing first 8,000 characters — download PDF for full document]